Q2 EPS Estimates for Rockwell Medical Cut by HC Wainwright

Rockwell Medical, Inc. (NASDAQ:RMTI) – Research analysts at HC Wainwright lowered their Q2 2025 EPS estimates for Rockwell Medical in a report released on Monday, November 25th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.01) per share for the quarter, down from their previous estimate of $0.02. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q3 2025 earnings at ($0.01) EPS and Q4 2025 earnings at $0.01 EPS.

RMTI has been the subject of a number of other reports. RODMAN&RENSHAW raised Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th. StockNews.com downgraded Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Rodman & Renshaw assumed coverage on Rockwell Medical in a research note on Thursday, November 14th. They issued a “buy” rating and a $5.00 price objective on the stock.

Rockwell Medical Trading Up 2.7 %

NASDAQ:RMTI opened at $2.31 on Tuesday. Rockwell Medical has a 12 month low of $1.16 and a 12 month high of $5.15. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $3.50 and its 200 day moving average is $2.66. The stock has a market capitalization of $74.66 million, a PE ratio of -46.20 and a beta of 1.50.

Institutional Investors Weigh In On Rockwell Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of RMTI. Armistice Capital LLC grew its position in shares of Rockwell Medical by 22.5% in the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock valued at $5,670,000 after purchasing an additional 592,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in Rockwell Medical by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock valued at $1,856,000 after buying an additional 43,302 shares in the last quarter. Jane Street Group LLC purchased a new position in Rockwell Medical during the 3rd quarter valued at about $534,000. Walleye Capital LLC bought a new stake in shares of Rockwell Medical during the third quarter valued at about $435,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Rockwell Medical by 877.1% in the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock worth $181,000 after buying an additional 92,189 shares in the last quarter. Institutional investors own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.